Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis

Abstract

Introduction There has been no consensus on whether and how long add-on drugs for augmentation therapy should be continued in the treatment of depression.

Methods Double-blind randomized controlled trials that examined the effects of discontinuation of drugs used for augmentation on treatment outcomes in patients with depression were identified. Meta-analyses were performed to compare rates of study withdrawal due to any reason, study-defined relapse, and adverse events between patients who continued augmentation therapy and those who discontinued it.

Results Seven studies were included (n=841 for continuing augmentation therapy; n=831 for discontinuing augmentation therapy). The rate of study withdrawal due to any reason was not significantly different between the 2 groups (risk ratio [RR]=0.86, 95% confidence interval [CI]=0.69–1.08, p=0.20). Study withdrawal due to relapse was less frequent in the continuation group than in the discontinuation group (RR=0.61, 95% CI=0.40–0.92, p=0.02); however, this statistical significance disappeared when one study using esketamine as augmentation was excluded. Analysis of the data from 5 studies that included a stabilization period before randomization found less frequent relapse in the continuation group than in the discontinuation group (RR=0.47, 95% CI=0.36–0.60, p<0.01). This finding was repeated when the esketamine study was excluded.

Discussion No firm conclusions could be drawn in light of the small number of studies included. Currently available evidence suggests that add-on drugs, other than esketamine, used for augmentation therapy for depression may be discontinued. This may not be the case for patients who are maintained with augmentation therapy after remission.

Key words

antidepressant - augmentation - depression - ketamine - relapse

Publication History

Received: 24 July 2020
Received: 28 October 2020

Accepted: 30 November 2020

Article published online:
23 December 2020

• References

• 1 Von Wolff A, Hölzel LP, Westphal A. et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis. J Affect Disord 2013; 144: 7-15
• 2 Williams N, Simpson AN, Simpson K. et al. Relapse rates with long-term antidepressant drug therapy: A meta-analysis. Hum Psychopharmacol 2009; 24: 401-408
• 3 John Rush A, Trivedi MH, Wisniewski SR. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Pychiatry 2006; 163: 1905-1917
• 4 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940
• 5 Corya SA, Williamson D, Sanger TM. et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364-372
• 6 Shelton RC, Williamson DJ, Corya SA. et al. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66: 1289-1297
• 7 Thase ME, Corya SA, Osuntokun O. et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68: 224-236
• 8 Kamijima K, Higuchi T, Ishigooka J. et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). J Affective Disord 2013; 151: 899-905
• 9 Berman RM, Fava M, Thase ME. et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009; 14: 197-206
• 10 Berman RM, Marcus RN, Swanink R. et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-853
• 11 Marcus RN, McQuade RD, Carson WH. et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156-165
• 12 Bauer M, Pretorius HW, Constant EL. et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70: 540-549
• 13 El-Khalili N, Joyce M, Atkinson S. et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917-932
• 14 Keitner GI, Garlow SJ, Ryan CE. et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43: 205-214
• 15 Mahmoud RA, Pandina GJ, Turkoz I. et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147: 593-602
• 16 [Anonymous] Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. American Psychiatric Association; 2010
• 17 Lam RW, Kennedy SH, Grigoriadis S. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117: S26-S43
• 18 Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 11th ed. Chichester, England: Wiley-Blackwell; 2018
• 19 Uchida H, Takeuchi H, Graff-Guerrero A. et al. Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol 2011; 31: 497-502
• 20 Gao K, Kemp DE, Ganocy SJ. et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol 2008; 28: 203-209
• 21 Zhang JP, Gallego JA, Robinson DG. et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16: 1205-1218
• 22 Sakurai H, Bies RR, Stroup ST. et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 2013; 39: 564-574
• 23 Ray WA, Chung CP, Murray KT. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235
• 24 Goodwin FmedSci GM, Geddes JR, Geddes JR. et al. Lithium toxicity profile: A systematic review and meta-analysis. Lancet 2012; 379: 721-728
• 25 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 ed. The Cochrane Collaboration; 2011
• 26 Higgins JPT, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 27 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 28 Hardy BG, Shulman KI, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. J Clin Psychopharmacol 1997; 17: 22-26
• 29 Bauer M, Bschor T, Kunz D. et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435
• 30 Rapaport MH, Gharabawi GM, Canuso CM. et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacol 2006; 31: 2505-2513
• 31 Alexopoulos GS, Canuso CM, Gharabawi GM. et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16: 21-30
• 32 Brunner E, Tohen M, Osuntokun O. et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacol 2014; 39: 2549-2559
• 33 Oakes TM, Dellva MA, Waterman K. et al. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Cur Med Res Opin 2015; 31: 1179-1189
• 34 Daly EJ, Trivedi MH, Janik A. et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019; 76: 893-903
• 35 Perlis RH, Brown E, Baker RW. et al. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 2006; 163: 225-231
• 36 Berman RM, Cappiello A, Anand A. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354
• 37 Newport DJ, Carpenter LL, McDonald WM. et al. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950-966
• 38 Singh JB, Fedgchin M, Daly EJ. et al. A Double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 2016; 173: 816-826
• 39 Wilkinson ST, Ballard ED, Bloch MH. et al. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am J Psychiatry 2018; 175: 150-158
• 40 Phillips JL, Norris S, Talbot J. et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Am J Psychiatry 2019; 176: 401-409
• 41 Ritter P, Findeis H, Bauer M. Ketamine in the treatment of depressive episodes. Pharmacopsychiatry 2020; 53: 45-50
• 42 Spielmans GI, Berman MI, Linardatos E. et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLOS Medicine 2013; 10: e1001403
• 43 Gao K, Ganocy SJ, Gajwani P. et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008; 69: 302-309
• 44 Ball SG, Ferguson MB, Martinez JM. et al. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Clin Psychiatry 2016; 77: 635-642